• Company
    • Overview
    • Disease Focus
    • Corporate Management
    • Board of Directors
    • Corporate and social responsibility
  • Technology
    • Small Molecule Therapeutics
    • The Endocannabinoid System
  • Pipeline
    • Overview & Timeline
    • URB937
    • URB597
    • Partnerships
  • News
  • Investors
  • Contact

Making a difference in people's lives. Exxel Pharma is a pharmaceutical company focused on the development of innovative, small molecule based medicines for management of chronic cough, pain and CNS disorders.

Learn More

Advancing Science and Medicines that matter. Exxel Pharma is pioneering novel therapies for chronic cough, pain and CNS disorders.

Learn More

Accelerating development and commercialization through high impact relationships and alliances.

Learn More

Exxel Pharma

  • Our Company

    Exxel Pharma is a development stage company that combines world-class leadership, know-how and industry experience to develop medicines for significant unmet medical needs.

  • Disease Focus

    Exxel Pharma is focused on development of small-molecule therapeutics for safe, non-addictive treatment of a chronic cough, pain and CNS disorders.

  • Project Pipeline

    Exxel Pharma’s pipeline counts two functionally distinct FAAH inhibitors, URB597 and URB937. URB597 is globally active, whereas URB937 is peripherally restricted. Both molecules were developed at UC Irvine and enhance endocannabinoid signaling.

  • The Endocannabinoid System

    The endocannabinoid system is composed of endocannabinoids and cannabinoid receptors, and is involved in the regulation of key physiological and pathological processes. Endocannabinoids are natural, lipid-based signaling molecules.

Company Profile

Exxel Pharma is a private, development stage company managed by a team of experienced biotech executives and entrepreneurs. The Company is focused on development of small-molecule therapeutics for chronic cough, pain and CNS disorders.

Exxel’s two lead therapeutics, URB937 and URB597, were developed at the University of California, Irvine (UCI), and are covered by multiple issued and pending patents.

In The News

  • Exxel’s CSO Daniele Piomelli receives Entrepreneurial Leader of the Year award from UC Irvine (UCI) Beall Applied Innovation

  • NEW YORK TIMES: At 71, She’s Never Felt Pain or Anxiety. Now Scientists Know Why.

  • University of Malta scientists speak of ‘safe way to block seizures with endocannabinoids’

  • Home
  • Company
  • Technology
  • Pipeline
  • News
  • Investors
  • Contact

© 2023 Exxcel Pharma

  • Privacy Policy
  • Site Map